The explosion of therapeutic options for Stage IV disease has heralded improved outcomes for patients with Stage IV melanoma. However, this expanded array of available options brings increased complexity for decision making. This activity, Stage IV Melanoma: Strategies to Support Shared Decision Making, uses cases to illustrate state-of-the art management of Stage IV melanoma, with a particular emphasis on how to use the AIM at Melanoma Stage IV melanoma decision-making support tool Stage IV melanoma decision-making support tool and Patient Action Plans to support shared decision making. The faculty will also illustrate effective communication strategies in these case simulations. Multidisciplinary approaches will be encouraged, addressing strategies to provide consistent education and engagement across the oncology care team.
Release Date: June 2, 2022
Expiration Date: June 1, 2023
Estimated Time to Complete the Activity: 1.5 hours
Media: Interactive, text-based activity
This activity is intended for oncology care providers (including physicians, advanced practice providers, nurses, and other HCPs) who care for patients with melanoma.
Upon completing this activity, the participant should be better able to:
Anna Pavlick, BSN, MSc, DO, MBA
Professor of Medicine in Hematology & Medical Oncology
Weill Cornell Medicine Cutaneous Oncology Program
Sunandana Chandra, MD, MS
Associate Professor of Medicine in Hematology and Oncology
Northwestern University Feinberg School of Medicine
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM); Terranova Medica, LLC; and AIM at Melanoma Foundation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 1.4 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COIs) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Anna Pavlick, BSN, MSc, DO, MBA
Grant/Research support:
Replimune
Speakers Bureau/Honoraria for non-CME:
Bristol Myers Squibb
Consultancy/Advisory Board:
Bristol Myers Squibb, Regeneron, Merck
Sunanda Chandra, MD, MS
Grant/research support:
Bristol Myers Squibb, Novartis Pharmaceuticals, Pfizer Inc. Exicure, EMD Serono, Regeneron, Sanfoi-Genzyme
Consultancy/Advisory Board:
Bristol Myers Squibb, Novartis Pharmaceuticals, Pfizer Inc. Exicure, EMD Serono, Regeneron, Sanfoi-Genzyme
The PIM, Terranova, and AIM at Melanoma Foundation planners and managers have nothing to disclose.
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
Internet
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).
Terranova Medica, LLC, and PIM are committed to protecting the privacy of those who choose to participate in activities on aimatcancerce.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
Terranova Medica, LLC, and PIM do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no charge for this activity.
Jointly provided by the Postgraduate Institute for Medicine; Terranova Medica, LLC; and AIM at Melanoma Foundation.
This activity is supported by independent educational grants from Novartis Pharmaceuticals and Merck & Co, Inc.
For further information, contact Tom Davis by telephone (877-276-4523), or by email (tdavis@terranovamedica.com).
If you have any questions regarding the CME/CE certification for this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.
Copyright © 2022 AIM at Melanoma Foundation; PIM, and Terranova Medica. LLC.
Jointly provided by Postgraduate Institute for Medicine, Terranova Medica, LLC, and AIM at Melanoma Foundation.